BioXcel Therapeutics (FRA:BX2) ROE % Adjusted to Book Value : 0.00% (As of Sep. 2024)

View and export this data going back to 2018. Start your Free Trial

What is BioXcel Therapeutics ROE % Adjusted to Book Value?

BioXcel Therapeutics's ROE % for the quarter that ended in Sep. 2024 was 0.00%. BioXcel Therapeutics's PB Ratio for the quarter that ended in Sep. 2024 was N/A. BioXcel Therapeutics's ROE % Adjusted to Book Value for the quarter that ended in Sep. 2024 was N/A.

BioXcel Therapeutics ROE % Adjusted to Book Value Historical Data

The historical data trend for BioXcel Therapeutics's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioXcel Therapeutics ROE % Adjusted to Book Value Chart

BioXcel Therapeutics Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROE % Adjusted to Book Value

Get a 7-Day Free Trial

-15.45

-12.36

-19.58

-15.53

BioXcel Therapeutics Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
ROE % Adjusted to Book Value	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of BioXcel Therapeutics's ROE % Adjusted to Book Value

For the Biotechnology subindustry, BioXcel Therapeutics's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BioXcel Therapeutics's ROE % Adjusted to Book Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioXcel Therapeutics's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where BioXcel Therapeutics's ROE % Adjusted to Book Value falls into.

BioXcel Therapeutics ROE % Adjusted to Book Value Calculation

BioXcel Therapeutics's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2023 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-1,589.62%	/	N/A
	=	N/A

BioXcel Therapeutics's ROE % Adjusted to Book Value for the quarter that ended in Sep. 2024 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	0.00%	/	N/A
	=	N/A

BioXcel Therapeutics ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of BioXcel Therapeutics's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.

BioXcel Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioXcel Therapeutics Inc (FRA:BX2) » Definitions » ROE % Adjusted to Book Value

Comparable Companies

Traded in Other Exchanges

BTAI:USA

Address

555 Long Wharf Drive, New Haven, CT, USA, 06511

Website

https://www.bioxceltherapeutics.com

BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.

BioXcel Therapeutics Headlines

No Headlines